Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 25;37(9):2012-2031.
doi: 10.1093/humrep/deac166.

Development of a core outcome set and outcome definitions for studies on uterus-sparing treatments of adenomyosis (COSAR): an international multistakeholder-modified Delphi consensus study

T Tellum  1 , J Naftalin  2 , C Chapron  3 , M Dueholm  4 , S-W Guo  5 , M Hirsch  6 , E R Larby  7 , M G Munro  8 , E Saridogan  2 , Z M van der Spuy  9 , D Jurkovic  2
Affiliations

Development of a core outcome set and outcome definitions for studies on uterus-sparing treatments of adenomyosis (COSAR): an international multistakeholder-modified Delphi consensus study

T Tellum et al. Hum Reprod. .

Abstract

Study question: What outcomes should be reported in all studies investigating uterus-sparing interventions for treating uterine adenomyosis?

Summary answer: We identified 24 specific and 26 generic core outcomes in nine domains.

What is known already: Research reporting adenomyosis treatment is not patient-centred and shows wide variation in outcome selection, definition, reporting and measurement of quality.

Study design, size, duration: An international consensus development process was performed between March and December 2021. Participants in round one were 150 healthcare professionals, 17 researchers and 334 individuals or partners with lived experience of adenomyosis from 48 high-, middle- and low-income countries. There were 291 participants in the second round.

Participants/materials, setting, methods: Stakeholders included active researchers in the field, healthcare professionals involved in diagnosis and treatment, and people and their partners with lived experience of adenomyosis. The core component of the process was a 2-step modified Delphi electronic survey. The Steering Committee analysed the results and created the final core outcome set (COS) in a semi-structured meeting.

Main results and the role of chance: A total of 241 outcomes was identified and distilled into a 'long list' of 71 potential outcomes. The final COS comprises 24 specific and 26 generic core outcomes across nine domains, including pain, uterine bleeding, reproductive outcomes, haematology, urinary system, life impact, delivery of care, adverse events and reporting items, all with definitions provided by the Steering Committee. Nineteen of these outcomes will apply only to certain study types. Although not included in the COS, the Steering Committee recommended that three health economic outcomes should be recorded.

Limitations, reasons for caution: Patients from continents other than Europe were under-represented in this survey. A lack of translation of the survey might have limited the active participation of people in non-English speaking countries. Only 58% of participants returned to round two, but analysis did not indicate attrition bias. There is a significant lack of scientific evidence regarding which symptoms are caused by adenomyosis and when they are related to other co-existent disorders such as endometriosis. As future research provides more clarity, the appropriate review and revision of the COS will be necessary.

Wider implications of the findings: Implementing this COS in future studies on the treatment of adenomyosis will improve the quality of reporting and aid evidence synthesis.

Study funding/competing interest(s): No specific funding was received for this work. T.T. received a grant (grant number 2020083) from the South Eastern Norwegian Health Authority during the course of this work. T.T. receives personal fees from General Electrics and Medtronic for lectures on ultrasound. E.R.L. is the chairman of the Norwegian Endometriosis Association. M.G.M. is a consultant for Abbvie Inc and Myovant, receives research funding from AbbVie and is Chair of the Women's Health Research Collaborative. S.-W.G. is a board member of the Asian Society of Endometriosis and Adenomyosis, on the scientific advisory board of the endometriosis foundation of America, previous congress chair for the World Endometriosis Society, for none of which he received personal fees. E.S. received outside of this work grants for two multicentre trials on endometriosis from the National Institute for Health Research UK, the Rosetrees Trust, and the Barts and the London Charity, he is a member of the Medicines and Healthcare Products Regulatory Agency (MHRA), Medicines for Women's Health Expert Advisory Group, he is an ambassador for the World Endometriosis Society, and he received personal fees for lectures from Hologic, Olympus, Medtronic, Johnson & Johnson, Intuitive and Karl Storz. M.H. is member of the British Society for Gynaecological Endoscopy subcommittee. No other conflict of interest was declared.

Trial registration number: N/A.

Keywords: Delphi; adenomyosis; core outcome set; outcomes; patient centredness; quality of care; quality of life; reporting; stakeholder.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart illustrating the Delphi process with inclusion and exclusion of potential outcomes for studies on uterus-sparing treatments of adenomyosis.
Figure 2.
Figure 2.
World map, colours indicating the number of participants from each country.
See this image and copyright information in PMC

Similar articles

  • ESHRE guideline: endometriosis.
    Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K, Saridogan E, Tomassetti C, van Hanegem N, Vulliemoz N, Vermeulen N; ESHRE Endometriosis Guideline Group. Becker CM, et al. Hum Reprod Open. 2022 Feb 26;2022(2):hoac009. doi: 10.1093/hropen/hoac009. eCollection 2022. Hum Reprod Open. 2022. PMID: 35350465 Free PMC article.
  • A core outcome set for future male infertility research: development of an international consensus.
    Rimmer MP, Howie RA, Anderson RA, Barratt CLR, Barnhart KT, Beebeejaun Y, Bertolla RP, Bortoletto P, Brannigan RE, Cantineau AEP, Caroppo E, Collura BL, Coward K, Duncan WC, Eisenberg ML, Gellatly SA, De Geyter C, Goulis DG, Henkel RR, Ho VNA, Hussein AF, Huyser C, Kadijk JH, Kamath MS, Khashaba S, Khattak H, Kobori Y, Kopeika J, Kucuk T, Luján S, Matsaseng TC, Mathur RS, McEleny K, Mitchell RT, Mol BW, Murage AM, Ng EHY, Pacey A, Perheentupa AH, Du Plessis S, Rives N, Sarris I, Schlegel PN, Shabbir M, Śmiechowski M, Subramanian V, Sunkara SK, Tarlarzis BC, Tüttelmann F, Vail A, van Wely M, Vazquez-Levin MH, Vuong LN, Wang AY, Wang R, Duffy JMN, Farquhar CM, Niederberger C. Rimmer MP, et al. Hum Reprod. 2025 May 1;40(5):865-875. doi: 10.1093/humrep/deaf039. Hum Reprod. 2025. PMID: 40233940 Free PMC article.
  • Evidence-based guideline: premature ovarian insufficiency.
    Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, Gravholt CH, Kalantaridou S, Kallen A, Kim KQ, Misrahi M, Mousa A, Nappi RE, Rocca WA, Ruan X, Teede H, Vermeulen N, Vogt E, Vincent AJ; ESHRE, ASRM, CREWHIRL, and IMS Guideline Group on POI. Panay N, et al. Hum Reprod Open. 2024 Dec 9;2024(4):hoae065. doi: 10.1093/hropen/hoae065. eCollection 2024. Hum Reprod Open. 2024. PMID: 39660328 Free PMC article.
  • Top 10 priorities for future infertility research: an international consensus development study.
    Duffy JMN, Adamson GD, Benson E, Bhattacharya S, Bhattacharya S, Bofill M, Brian K, Collura B, Curtis C, Evers JLH, Farquharson RG, Fincham A, Franik S, Giudice LC, Glanville E, Hickey M, Horne AW, Hull ML, Johnson NP, Jordan V, Khalaf Y, Knijnenburg JML, Legro RS, Lensen S, MacKenzie J, Mavrelos D, Mol BW, Morbeck DE, Nagels H, Ng EHY, Niederberger C, Otter AS, Puscasiu L, Rautakallio-Hokkanen S, Sadler L, Sarris I, Showell M, Stewart J, Strandell A, Strawbridge C, Vail A, van Wely M, Vercoe M, Vuong NL, Wang AY, Wang R, Wilkinson J, Wong K, Wong TY, Farquhar CM; Priority Setting Partnership for Infertility. Duffy JMN, et al. Fertil Steril. 2021 Jan;115(1):180-190. doi: 10.1016/j.fertnstert.2020.11.014. Epub 2020 Nov 30. Fertil Steril. 2021. PMID: 33272617
  • A systematic review of outcome reporting and outcome measures in studies investigating uterine-sparing treatment for adenomyosis.
    Tellum T, Omtvedt M, Naftalin J, Hirsch M, Jurkovic D. Tellum T, et al. Hum Reprod Open. 2021 Aug 7;2021(3):hoab030. doi: 10.1093/hropen/hoab030. eCollection 2021. Hum Reprod Open. 2021. PMID: 34466664 Free PMC article. Review.
See all similar articles

Cited by

References

    1. Anderson DJ, Podgorny K, Berríos-Torres SI, Bratzler DW, Dellinger EP, Greene L, Nyquist A-C, Saiman L, Yokoe DS, Maragakis LL. et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:605–627. - PMC - PubMed
    1. Beckstead JW. On measurements and their quality. Paper 4: verbal anchors and the number of response options in rating scales. Int J Nurs Stud 2014;51:807–814. - PubMed
    1. Bourdon M, Santulli P, Oliveira J, Marcellin L, Maignien C, Melka L, Bordonne C, Millisher AE, Plu-Bureau G, Cormier J. et al. Focal adenomyosis is associated with primary infertility. Fertil Steril 2020;114:1271–1277. - PubMed
    1. Bruun MR, Arendt LH, Forman A, Ramlau-Hansen CH.. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018;97:1073–1090. - PubMed
    1. Centers for Disease Control and Prevention. Measuring Healthy Days. Atlanta, GA: CDC, 2000. https://www.cdc.gov/hrqol/pdfs/mhd.pdf (1 May 2022, date last accessed).

Publication types